Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call
Vivos Therapeutics (NASDAQ: VVOS) is set to announce its Q2 2022 financial results after market close on August 15, 2022. A conference call will follow at 5:00 PM ET that day to discuss the results and company milestones. Vivos specializes in treatments for dentofacial abnormalities and conditions like obstructive sleep apnea (OSA), with its Vivos Method providing a non-invasive solution to approximately 28,000 patients treated globally. The call can be accessed via dial-in or online webcast, with a replay available until August 29, 2022.
- Company provides unique non-invasive treatment for OSA, with proven effectiveness in around 28,000 patients.
- Growing interest in the Vivos Method, indicated by the upcoming financial results announcement and conference call.
- None.
Call Scheduled for Monday, August 15, 2022 at 5:00 pm ET
LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it plans to release financial results for the second quarter ended June 30, 2022 after market close on Monday, August 15, 2022. The Company will conduct a conference call the same day at 5:00 pm (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and developments.
To access the conference call, please dial (800) 458-4121, or for international callers, (720) 543-0206. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 3922772. The replay will be available until August 29, 2022.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution. It has proven effective in approximately 28,000 patients treated worldwide by more than 1,600 trained dentists.
The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim,” “may,” “could,” “should,” “expects,” “projects,” “intends,” “plans,” “believes,” “predicts,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Julie Gannon
Investor Relations Officer
720-442-8113
jgannon@vivoslife.com
Vivos Media Relations Contact:
Amy Cook
Public Relations Officer
949-813-0182
acook@vivoslife.com
FAQ
When will Vivos Therapeutics release its Q2 2022 financial results?
What time is the Vivos Therapeutics conference call scheduled?
How can I access the Vivos Therapeutics conference call?
What innovative treatments does Vivos Therapeutics offer?
How many patients has Vivos Therapeutics treated?
